PMID- 29912844
OWN - NLM
STAT- MEDLINE
DCOM- 20190516
LR  - 20190516
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Linking)
VI  - 37
IP  - 9
DP  - 2018 Sep
TI  - Antibody Persistence up to 3 Years After Primary Immunization With Inactivated 
      Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a 
      Booster Dose.
PG  - e233-e240
LID - 10.1097/INF.0000000000002124 [doi]
AB  - BACKGROUND: An inactivated Vero cell culture derived Japanese encephalitis virus 
      vaccine (IXIARO) requires a booster dose 1 year after primary schedule for 
      long-term antibody persistence in adults. The aim of this study is to evaluate 
      immunogenicity and safety of a booster dose in children 2 months to <18 years of 
      age. METHODS: This is a randomized, controlled open-label study in the 
      Philippines. Three hundred children vaccinated with IXIARO in a previous trial 
      were randomized 1:1 to receive either no booster or a booster 12 months after 
      initiation of the primary series. Neutralizing antibody titers were assessed 
      before and after the booster and up to 3 years after primary series. Safety 
      endpoints included the rate of subjects with solicited adverse events (AEs), 
      unsolicited AEs and serious AEs within 1 month after the booster. RESULTS: 
      Geometric mean titer declined by 1 year after the primary series, but titers 
      remained above the established protective threshold in 85%-100% of children 
      depending on age group. The booster led to a pronounced increase in geometric 
      mean titer and 100% seroprotection rate in all age groups. The booster was well 
      tolerated, with AE rates lower compared with the primary series. Most AEs were 
      mild. CONCLUSIONS: A booster dose of IXIARO administered 12 months after the 
      primary immunization was well tolerated and highly immunogenic.
FAU - Kadlecek, Vera
AU  - Kadlecek V
AD  - From the Valneva Austria GmbH, Vienna, Austria.
FAU - Borja-Tabora, Charissa Fay
AU  - Borja-Tabora CF
AD  - Department of Health, Research Institute for Tropical Medicine, Manila, 
      Philippines.
FAU - Eder-Lingelbach, Susanne
AU  - Eder-Lingelbach S
AD  - From the Valneva Austria GmbH, Vienna, Austria.
FAU - Gatchalian, Salvacion
AU  - Gatchalian S
AD  - Department of Pediatrics.
AD  - College of Medicine, University of the Philippines, Manila, Philippines.
AD  - Section of Infectious and Tropical Diseases, Department of Pediatrics, Philippine 
      General Hospital, Manila, Philippines.
AD  - Department of Health, Research Institute for Tropical Medicine, Muntinlupa, 
      Philippines.
FAU - Kiermayr, Sigrid
AU  - Kiermayr S
AD  - From the Valneva Austria GmbH, Vienna, Austria.
FAU - Sablan, Benjamin Jr
AU  - Sablan B Jr
AD  - Department of Pediatrics.
FAU - Kundi, Michael
AU  - Kundi M
AD  - Center for Public Health, Medical University of Vienna, Austria.
FAU - Taucher, Christian
AU  - Taucher C
AD  - From the Valneva Austria GmbH, Vienna, Austria.
FAU - Dubischar, Katrin L
AU  - Dubischar KL
AD  - From the Valneva Austria GmbH, Vienna, Austria.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Japanese Encephalitis Vaccines)
RN  - 0 (Vaccines, Inactivated)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Neutralizing/blood
MH  - Antibodies, Viral/*blood
MH  - Child
MH  - Child, Preschool
MH  - Encephalitis, Japanese/immunology/*prevention & control
MH  - Humans
MH  - Immunization, Secondary
MH  - *Immunogenicity, Vaccine
MH  - Infant
MH  - Japanese Encephalitis Vaccines/administration & dosage/*therapeutic use
MH  - Male
MH  - Philippines
MH  - Vaccines, Inactivated/administration & dosage/therapeutic use
EDAT- 2018/06/19 06:00
MHDA- 2019/05/17 06:00
CRDT- 2018/06/19 06:00
PHST- 2018/06/19 06:00 [pubmed]
PHST- 2019/05/17 06:00 [medline]
PHST- 2018/06/19 06:00 [entrez]
AID - 10.1097/INF.0000000000002124 [doi]
PST - ppublish
SO  - Pediatr Infect Dis J. 2018 Sep;37(9):e233-e240. doi: 
      10.1097/INF.0000000000002124.